Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model

This publication has 20 references indexed in Scilit:

• Recombinant human endostatin administered as a 28-day continuous intravenous infusion, followed by daily subcutaneous injections: a phase I and pharmacokinetic study in patients with advanced cancer
  Annals of Oncology, 2005
• Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model
  Clinical Cancer Research, 2005
• Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.
  2004
• Expression of the Type-1 Repeats of Thrombospondin-1 Inhibits Tumor Growth Through Activation of Transforming Growth Factor-β
  The American Journal of Pathology, 2004
• Inhibition of Vascular Endothelial Growth Factor (VEGF) Signaling in Cancer Causes Loss of Endothelial Fenestrations, Regression of Tumor Vessels, and Appearance of Basement Membrane Ghosts
  The American Journal of Pathology, 2004
• Tumor progression: the effects of thrombospondin-1 and -2
  The International Journal of Biochemistry & Cell Biology, 2004
• The application of an antiangiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts
  Cancer Gene Therapy, 2000
• Effect of Angiostatin on Liver Metastasis of Pancreatic Cancer in Hamsters
  Japanese Journal of Cancer Research, 2000
• Overexpression of Thrombospondin-1 Decreases Angiogenesis and Inhibits the Growth of Human Cutaneous Squamous Cell Carcinomas
  The American Journal of Pathology, 1999
• A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.
  Proceedings of the National Academy of Sciences, 1990